Project description:Single-cell RNA-sequencing analyses were performed on pancreatic tumors from KPPC mice and PPSSC mice, so as to identify the changes of tumor immune microenvironment upon Trp53 and Smad4 deletion without KRAS mutation.
Project description:Single-cell RNA-sequencing analyses were performed on unfractionated live cell mixtures from pancreatic tumors of KPC mice and wild-type mice to detect different myCAF subpopulations
Project description:Single-cell ATAC-sequencing analyses were performed on unfractionated live cell mixtures from pancreatic tumors of KPC mice and wild-type mice to better understand the epigenetic characteristics of different cell populations
Project description:We employed dual-recombinase genetic mouse models of spontaneous PDAC mice (KPPF;Col1smaKO) to delete Col1 (type I collagen) specifically in myofibroblasts, in comparison with control KPPF mice. Single-cell RNA-sequencing analyses were performed on unfractionated live cell mixtures from pancreatic tumors of KPPF mice and KPPF;Col1smaKO mice, to investigate the impact of myofibroblast-specific Col1 deletion on tumor microenvironment.
Project description:Circulating Tumor Cells (CTCs) are shed from primary tumors into the bloodstream, mediating the hematogenous spread of cancer to distant organs. Using a pancreatic cancer mouse model, we applied a microfluidic device to isolate CTCs independently of tumor epitopes, subjecting these to single cell RNA-sequencing. This study was conducted to determine the heterogeneity of pancreatic CTCs and to compare these CTCs to matched primary tumors, cell line controls (NB508 cancer cell line and MEF non-cancer cell line), primary tumor single cells, and normal leukocytes/WBCs. We profiled RNA from 75 single cells circulating in mouse blood enriched for circulating tumor cells from 5 mice, 12 single cells from a mouse embryonic fibroblast cell line, 16 single cells from the nb508 mouse pancreatic cancer cell line, 12 single mouse white blood cells, 18 single GFP lineage-traced circulating tumor cells from two mice, 20 single GFP lineage-traced cancer cells from the primary pancreatic tumor of a mouse, and 34 dilutions to 10 or 100 picograms of total RNA from mouse primary pancreatic tumors from 4 mice.
Project description:RNA-sequencing analyses were performed on cancer cell lines from KPPC and PPSSC pancreatic tumors, so as to identify the changes of tumor immune microenvironment upon Trp53 and Smad4 deletion without KRAS mutation.
Project description:KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi- kinase inhibitor nintedanib. Using single cell RNA sequencing and immunophenotyping, we show that the combination therapy reprograms the immunosuppressive microenvironment and primes cytotoxic and memory T cells to infiltrate the tumors, thereby sensitizing mesenchymal PDAC to PD-L1 inhibition.